Eritoran

Eisai slumped 5% after the drugmaker said on Tuesday it has decided not to seek marketing approval for its sepsis drug Eritoran by the end of March as previously planned.

Asia Markets Mixed Shri Navaratnam 2011

Eisai fell 5% a day after reporting a setback in developing Eritoran, a drug for severe sepsis.

Widespread Gains for Shares Barbara Kollmeyer 2011

Shares in Eritoran, and the other drugs the group is trying to push through its late-stage pipeline, is important because once

SeekingAlpha.com: Home Page EP Vantage 2010

Trial Also Evaluated 28-Day All-Cause Mortality of Eritoran, a Toll-Like Receptor 4 Antagonist Health Organisation (WHO) denied on Tuesday that it was unduly influenced by drugs companies to exaggerate the dangers of the H1N1 flu

WN.com - Business News 2010

Eritoran aims to block the activation of toll-like receptor 4 (TLR4), which is part of the immune system and when activated is thought to contribute to the cascade that causes severe sepsis.

SeekingAlpha.com: Home Page EP Vantage 2010

Eisai's Sepsis Drug Eritoran Fails to Save More Lives in Final-Stage Study

Earnings Preview: Eli Lilly - Yahoo! Finance 2011

Eisai's Sepsis Drug Eritoran Fails to Save More Lives in Final-Stage Study

Earnings Preview: Eli Lilly - Yahoo! Finance 2011

Trial Also Evaluated 28-Day All-Cause Mortality of Eritoran, a Toll-Like Receptor 4 Antagonist

WN.com - Articles related to China media accuse Google of violating promises 2010

Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis

WN.com - Articles related to China media accuse Google of violating promises 2010

Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis

WN.com - Articles related to Children missing out on vital sleep thanks to video games and TV 2010